Thoracic aortic aneurysm (TAA) is a potentially life-threatening condition in that it places patients at risk for aortic dissection (AoD) or rupture. Nevertheless, our modern understanding of the pathogenesis of TAA is quite limited. A genetic predisposition to TAA has been established, and gene discovery in affected families has identified two major categories of gene alterations. The first involves mutations in genes encoding various components of the transforming growth factor beta (TGF-β) signaling cascade (FBN1, TGFBR1, TGFBR2, TGFB2, TGFB3, SMAD2, SMAD3 and SKI), and these conditions are known collectively as the TGF-β vasculopathies (TGFβVs). The second set of genes encodes components of the smooth muscle contractile apparatus (ACTA2, MYH11, MYLK, and PRKG1), a group termed the smooth muscle contraction vasculopathies (SMCVs). Mechanistic hypotheses based on these discoveries have shaped rational therapies, some of which are under clinical evaluation. This review will discuss published data on genes involved in TAA and attempt to explain divergent hypotheses of aneurysm etiology.